Indications of Lenvatinib

1.Differentiated Thyroid Cancer

lenvatinib is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).  

2.Renal Cell Carcinoma

lenvatinib, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). lenvatinib, in combination with everolimus, is indicated for the treatment of adult patients  with advanced RCC following one prior anti-angiogenic therapy.  

3.Hepatocellular Carcinoma

lenvatinib is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).  

4.Endometrial Carcinoma

lenvatinib, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR), as determined by an FDA-approved test, or not microsatellite instability-high (MSI-H), who have disease progression following prior systemic therapy in any setting and are not  candidates for curative surgery or radiation.

from FDA，2024.06